Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Patel, Keyur P., Newberry, Kate J., Luthra, Rajyalakshmi, Jabbour, Elias, Pierce, Sherry, Cortes, Jorge, Singh, Rajesh, Mehrotra, Meenakshi, Routbort, Mark J., Luthra, Madan, Manshouri, Taghi, Santos, Fabio P., Kantarjian, Hagop, Verstovsek, Srdan
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2015
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528066/
https://ncbi.nlm.nih.gov/pubmed/26124496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-633404
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы